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Abstract 
Background: Peroxisome proliferator-activated receptor γ2 (PPARγ2) is a nuclear receptor that regulates adipo-
cyte differentiation, lipid metabolism, and insulin sensitivity. The aim of this study was to investigate the asso-
ciation between the Pro12Ala single nucleotide polymorphism (SNP) at the PPARγ2 gene and type II diabetes 
(T2DM) and obesity in an Iranian population. 
Methods: The genomic DNA of the 312 subjects included four groups: (1) nonobese with type II diabetes, (2) obese 
without type II diabetes, (3) obese with type II diabetes, and (4) nondiabetic nonobese controls. The Pro12Ala 
polymorphism was detected by polymerase chain reaction–restriction fragment length polymorphism (PCR-
RFLP) analysis. 
Results: Frequencies of the Ala allele in obese subjects were signifi cantly different from those control subjects 
(odds ratio [OR], 2.358; 95% confi dence interval [CI], 1.101–5.05) (P =
 0.025). In contrast, no signifi cant association 
was detected between the Pro12Ala polymorphism and type II diabetes (OR, 0.652; 95% CI, 0.261–1.628). In all 
subjects, the Ala carriers had a higher body mass index (BMI) compared with the common allele. 
Conclusions: Our results showed that the Pro12Ala polymorphism in the PPARγ2 gene is associated with obe-
sity in Iranian subjects and the presence of the Ala allele could predict higher BMI. 
Introduction 
Obesity is caused by an imbalance between energy intake and expenditure, resulting in weight gain.1 The 
peroxisome proliferator activated receptor γ2 (PPARγ2) is an 
important transcription factor for lipid and glucose metab-
olism that belongs to the same family of nuclear receptors 
as steroid and thyroid hormone receptors,2,3 which have an 
essential role in adipogenesis and adipocyte gene expres-
sion. PPARγ1 and PPARγ2 are two isoforms arising from the 
PPARγ gene via differential promoter usage and alternative 
splicing. Human PPARγ2 has 28 additional amino acids at 
its amino terminus compared to PPARγ1 and is expressed 
almost exclusively in adipose tissues, whereas PPARγ1 is 
expressed in various tissues.2–4 
Obesity may be associated with elevated PPARγ expres-
sion. PPARγ mRNA levels in white adipose tissue are unaf-
fected in two murine models of obesity (gold thioglucose and 
ob/ob), but are increased up to 50% after high fat feeding in 
normal mice.5 PPARγ has an important role in adipocyte dif-
ferentiation and regulates expression of key enzymes in lipid 
metabolism (eg, lipoprotein lipase, fatty acid binding transfer 
proteins, and hormone-sensitive lipase) as well as insulin sen-
sitivity.3 Recently, the single nucleotide polymophism (SNP) 
CCA→GCA in codon 12 of exon B of the PPARγ2 gene was 
described in humans that resulted in the substitution of pro-
line by alanine.6 The aim of this study was to examine the asso-
ciation between mutation of Pro12Ala of the PPARγ2 gene and 
type II diabetes (T2DM) or obesity in an Iranian population. 
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Subjects and Methods 
Subjects 
In a cross-sectional study, 312 unrelated subjects were
recruited in the Tehran Homocysteine Survey.7,8 These sub-
jects, who were 25–64 years old, were selected by using a
population-based cluster sampling from 17th district of
Tehran. Subjects who volunteered to participate in the study
were divided into four groups: (1) 78 normal people as con-
trols (nonobese, nondiabetic), defi ned as those with a body
mass index (BMI) <25 kg/m2 and fasting blood sugar (FBS)
<110 mg/dL, (2) 78 obese subjects without T2DM, who had
a BMI >30 kg/m2 and FBS <110 mg/dL, (3) 78 nonobese
patients with T2DM with a BMI <30 kg/m2 and FBS >126
mg/dL, (4) 78 obese subjects with T2DM with BMI >30 kg/
m2 and FBS >126 mg/dL. 
Weight, height, blood pressure (BP), and waist-to-hip ratio
(WHR) were measured. Biochemical tests including total
cholesterol, high-density lipoprotein cholesterol (HDL-C),
triglyceride, and FBS were measured using an autoanalyzer
(Hitachi). 
Genotyping 
Genomic DNA was extracted from peripheral blood
leukocytes by the salting-out method.9 Exon B of the
PPARγ2 gene was amplifi ed by PCR using a sense primer
(5′-GCCAATTCAAGCCCAGTC-3′) and an antisense
primer (5′-GATATGTTTGCAGACAGT GTAT CAGT
GAAGGAATCGCTTTCCG-3′).6 
PCR conditions were an initial denaturation step at 95°C
for 5 minutes, followed by 30 cycles of 95°C for 1 minute,
annealing at 56°C for 1 minute, and extension 72°C for 1 mi-
nute with a fi nal extension step of 72°C for 10 minutes. The
PCR product was 270 bp long and was digested using 10 units
of BstUI restriction enzyme (Fermentas) at 37°C overnight.10
BstUI digests CG-GC only when the C→G substitution is
present at nucleotide 34. The expected products after diges-
tion with BstUI were 270 bp for  normal homozygous (Pro/
Pro); two bands of 270 and 227 bp for heterozygous (Pro/
Ala); and 270, 227, and 43 bp for homozygous (Ala/Ala). 
Statistical analysis 
Statistical analysis was carried out using SPSS software
version 11.5 for Windows. All results were expressed as
mean ± standard deviation (SD). The clinical and labora-
tory characteristics of cases and controls were compared
using two independent sample t-tests or chi-squared  tests,
as appropriate. Genotype distributions in cases and con-
trols were compared with the chi-squared test. Age and sex
were considered in the logistic regression model together
with genotype, study groups, and BMI, but they were not
signifi cantly related to the risk of T2DM and obesity (data
not shown), and therefore they were omitted from the fi nal
logistic regression model. A P value equal or less than 0.05
was considered signifi cant. 
Results 
Our population in the nonobese without T2DM group
included 36 males (46%) and 42 females (54%), obese without
T2DM subjects included 38 males (49%) and 40 females (51%),
nonobese with T2DM subjects included 37 males (47%) and 
41 females (53%), and obese with T2DM subjects included   
38 males (49%) and 40 females (51%). The biochemical and 
anthropometric parameters are summarized in Table 1  
according to PPARγ2 genotypes from 312 Iranian subjects. 
In the nonobese without T2DM group, subjects with PA/AA  
had a higher BMI than those with the common allele (PP)  
(P = 0.031) as well as a lower FBS level (P = 0.009). In the  
obese without T2DM group, the subjects with PA/AA had a 
higher BMI in comparison to individuals with the common  
allele (P = 0.033) and lower FBS (P = 0.026) as well as lower  
systolic (SBP) and diastolic blood pressure (DBP).  
In the nonobese with T2DM group, the PA/AA subjects  
had a higher BMI compared to the wild type (P = 0.027) and  
also a higher triglyceride (P = 0.002) and greater waist cir- 
cumference (P = 0.041). In the obese with T2DM group, the 
PA/AA subjects had higher BMI compared to the wild type  
(P = 0.003) as well as greater hip circumference (P ≤ 0.001).  
Table 2 shows the Ala allele frequencies of this SNP in our  
studied population. The Ala allele frequency in both non- 
obese without T2DM and obese without T2DM subjects was 
8.9% and 16.6%, respectively. A statistically signifi cant differ-
ence was detected between the obese without T2DM group 
and nonobese without T2DM group in allele frequency. The 
 odds ratio (OR) for association of the Ala allele with obesity 
 was 2.358 (95% confi dence interval [CI], 1.101–5.054). 
 The Ala allele frequency in nonobese with T2DM sub-
 jects was 5.76%, the OR for association of the Ala allele with 
 diabetes was 0.652 (95% CI, 0.261–1.628). The allele frequency 
in obese with T2DM subjects was 10.2%. OR for association 
 of the Ala allele with diabetes and obesity was 1.094 (95% CI, 
 0.477–2.508. 
We could not detect a signifi cant difference in Ala allele 
 frequency between nonobese with T2DM and nonobese 
 without T2DM groups as well as between the obese with 
  T2DM group and nonobese without T2DM group. 
 
Discussion 
 The PPARγ2 Pro12Ala polymorphism was fi rst identifi ed 
 by Yen et al.6 The frequency of the Ala allele varies across 
different ethnicities; it is low in Africans and Asians.6,11–13  
Many studies in Caucasians in different countries indicated 
that their Pro12Ala polymorphism was greater than 10%.6,14 
The frequency of the Ala12 allele in our study normal  
group (8.9%) was approximately similar to that reported by  
Muller et al.15; in our study obese group (16.6%), it was greater 
than that reported by Kolemainen et al.,16 and in our diabetic   
group (5.76%) it was approximately similar to that reported  
by Pinterova 17 and Ghoussiani.18 The frequency of the Ala 
allele in the diabetic obese group in our study (10.2%) was  
greater than those of Oh et al.10   
In the present study, we found a signifi cant association  
between obesity with Ala allele frequency. This result is  
consistent with several previous studies on PPARγ2 poly- 
morphism in different ethnic groups. Beamer et al. fi rst  
reported a signifi cant relationship between Pro12Ala poly-
morphism and obesity in nondiabetic Caucasians.19 Several 
studies showed similar observation. The Ala allele fre-
quency was also higher in obese subjects than in overweight 
 subjects.13,16,20,21 
 PPARγ2 is a key regulator of adipocyte differentiation 
 and energy storage. Reduced transcription of specifi c genes 
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Table 2. Comparison of Genotypic and Allelic Distribution of Pro12Ala Polymorphism in 
Study Populations versus Nonobese Without T2DM Subjects in Iranian Population 
Populations n 
PPAR genotypes Allelic frequencies 
Odds ratio 
(95% CI) 
PP allele PA/AA allele P A 
Percent n Percent n Percent n Percent 
Obese without 
T2DM (n = 78) 
Nonobese with 
T2DM (n = 78) 
Obese with T2DM 
(n = 78) 
Nonobese without 
T2DM (n = 78) 
53 
69 
64 
65 
67.9 
88.4 
82 
83.3 
25 
9 
14 
13 
32.1 
11.6 
18 
13.7 
130 
147 
140 
142 
83.4 
94.3 
89.8 
91.1 
26 
9 
16 
14 
16.6 
5.7 
10.2 
8.9 
2.358 (1.101–5.054)a 
0.652 (0.261–1.628)a 
1.094 (0.477–2.508)a 
 
P value for differences between obese without T2DM, nonobese with T2DM, and obese with T2DM subjects 
versus nonobese without T2DM subjects was obtained by the Fisher exact test. 
aP value is signifi cant. 
Abbreviations: T2DM, Type 2 diabetes mellitus; PPAR, peroxisome proliferator-activated receptor; CI, 
confi dence interval. 
(lipoprotein lipase and acyl-coenzyme A [CoA] oxidase) was 
reported for cells overexpressing the Ala variant compared 
with cells overexpressing the wild-type protein.22 These 
studies clearly indicate reduced transcriptional activity 
of PPARγ2 as a result of the Pro-to-Ala exchange. Because 
PPARγ2 is exclusively expressed in fat cells, any meta-
bolic effects of the polymorphism, including those on glu-
cose homeostasis, are likely to be secondary to alterations 
in adipose tissue. There is evidence from humans that the 
Pro12Ala polymorphism promotes the suppression of free 
fatty acid (FFA) release by insulin.23 It is unclear, however,   
which genes are specifi cally affected by the transcriptional 
changes conferred by the polymorphism. Conceivably, the 
proportion of large versus small adipocytes is involved. 
Activators of PPARγ2 have been shown to promote differ-
entiation of preadipocytes to small adipocytes, and in small 
adipocytes lipolysis is more insulin sensitive than in large 
adipocytes.22,24 
We found an association between Pro12Ala polymor-
phism and waist circumference in the diabetic group as well 
as hip circumference in the diabetic obese group, but not 
in the normal and obese groups. A recent Hispanic study 
did not fi nd this relation either with BMI or waist circum-
ference,25 although a previous study by this group had con-
fi rmed this relation.26 
Thus, these results support the role of the Pro12Ala 
polymorphism as the genetic risk factor for obesity in the 
Iranian population. In contrast, no association was reported 
with T2DM in our diabetic group. This result is consis-
tent with reports of other studies in Italians,27 Germans,28  
French,29,30 Polish,31 Arabian,32 Chinese,33 Czech,34 and
Pima Indian populations.15 In contrast, the protective role 
of the Ala allele against T2DM was reported by Altshuler 
in a metaanalysis that included over 3000 individuals,35 as 
well as other studies that reported the same results.12,36–38  
Boden et al. demonstrated that reduced availability of FFAs 
would permit muscle to use more glucose and the liver 
to suppress glucose production more effi ciently upon in-
sulin stimulation.39Although a previous study in Iran36 also 
showed this protective effect of the Ala allele, we did not 
detect such an effect due to small sample size. However, this 
protective effect has been reported more among Asian than 
European populations.38 
Our results showed that Ala12 carriers had signifi cantly 
higher BMI values. A metaanalysis from 30 independent 
studies with a total number of 19,136 subjects demonstrated 
that Ala12 carriers had signifi cantly higher BMI values than 
noncarriers.40 Other studies also reported higher BMI values 
in the Ala carriers,19,28,41 whereas others described a lower 
BMI in Ala carriers.42,43 There are some studies that could 
not fi nd any association at all.12,14,44 
A reason for higher BMI values in the Ala carriers may be 
due to the effect of environmental factors. In general, PPARγ 
expression is increased in the adipose tissue of obese sub-
jects, but a low-calorie diet can downregulate its expression.5  
It has been shown that when the dietary polyunsaturated fat-
to-saturated fat ratio is low, BMI in Ala12 carriers is greater 
than that in Pro12 homozygous carriers. However, when the 
dietary ratio is high, the opposite effect can be seen.45 Scacchi 
et al. observed a signifi cant inverse relationship between 
Ala frequency and T2DM prevalence mainly in populations 
in which the energy source from lipids exceeded 30% of the 
total energy intake. There is an increasing need to study 
the genetic structure of people now living in preindustrial 
societies where future changes in environmental factors, 
mainly dietary habits, could interfere with their genes and 
endanger their health.46 The gene–nutrient interaction may, 
in part, explain the disparate effect of the Ala12 variants on 
BMI in obese and lean subjects. 
We are aware of certain limitations of the study. It is pos-
sible that the number of patients studied was too small to 
detect a weak genotype–phenotype association. However, 
P values in practically all investigated genotype–phenotype 
relationships were far from 0.05, so it is diffi cult to imagine 
that increasing the sample size would signifi cantly change 
the results. Some authors propose using more stringent P 
values to explore such associations.47 Small sample size is an 
important limitation of the present study. 
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In summary, to the best of our knowledge this is the fi rst 
study performed in Iran regarding the Pro12Ala polymor-
phism. Given the relatively small size of the study sample, 
the results of present study revealed an association between 
the Ala polymorphism of the PPARγ2 gene and obesity. 
However, no association was seen between the Pro12Ala 
polymorphism in PPARγ2 gene and T2DM. 
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